All right. Thank you.
This is going to be a similar question in regard to investments in harm reduction. Perhaps there's some data because we've had some limited experience with this. We do know and we've talked a lot about supervised consumption sites and the prevention of fatalities when people overdose. We also know that there is a harm reduction aspect in the supply of clean injection equipment, which means that this would prevent the transmission of blood-borne diseases. We know that a single infection of HIV is going to cost several hundred thousand dollars in the life of a patient, while a single case of hepatitis C, if adequately treated, is going to cost several hundred thousand dollars a year per patient.
In the supervised consumption sites that have existed, is there any data on the decrease in the rates of transmission of blood-borne diseases in these centres?